Verona Pharma ( (VRNA) ) has released its Q4 earnings. Here is a breakdown of the information Verona Pharma presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Verona Pharma, a biopharmaceutical company, focuses on developing and commercializing innovative therapies for chronic respiratory diseases, with its first product, Ohtuvayre, targeting the maintenance treatment of COPD.